增强CT肝脏衰减值单独用于识别中度肝脂肪变性优于肝脾差值
在1676名接受统一CT尿路上皮方案的老年人中,门静脉期肝脏衰减值预测中度肝脂肪变性的AUROC为0.943,显著优于肝脾差值(AUROC=0.814,p<0.001)。门静脉期肝脏阈值80 HU和90 HU的敏感度/特异度分别为85.6%/89.6%和94.9%/74.7%,而肝脾差值-40 HU和-10 HU的敏感度/特异度分别为43.5%/90.0%和92.1%/52.5%。中度-重度脂肪变性肝脏的增强幅度显著低于轻度/无脂肪变性(平均35.7 HU vs 47.3 HU,p<0.001)。
要点
- 门静脉期肝脏衰减值单独预测中度肝脂肪变性优于肝脾差值。
- 门静脉期肝脏阈值80 HU和90 HU的敏感度/特异度分别为85.6%/89.6%和94.9%/74.7%。
- 中度-重度脂肪变性肝脏增强幅度更低(35.7 HU vs 47.3 HU,p<0.001)。
核心结论
- 中度肝脂肪变性可依据标准门静脉期CT的肝脏衰减值单独可靠诊断,脾脏衰减值的参考似乎价值有限。
研究设计与样本
- 回顾性分析1676名成人(平均年龄68.4±10.2岁;1045男/631女)接受CT尿路上皮方案,包括平扫、门静脉期和10分钟延迟期,使用经验证的深度学习工具自动分割肝脾衰减值(HU)。以平扫肝脏衰减<40.0 HU(对应MRI质子密度脂肪>15%)作为中度脂肪变性参考标准。
关键影像表现/征象
- 中度-重度脂肪变性肝脏的增强幅度显著低于轻度/无脂肪变性(平均35.7 HU vs 47.3 HU,p<0.001)。
诊断标准与关键数值
- 门静脉期肝脏衰减值预测中度肝脂肪变性的AUROC=0.943,显著优于肝脾差值(AUROC=0.814)(p<0.001)。
- 门静脉期肝脏阈值80 HU的敏感度/特异度为85.6%/89.6%。
- 门静脉期肝脏阈值90 HU的敏感度/特异度为94.9%/74.7%。
- 肝脾差值-40 HU的敏感度/特异度为43.5%/90.0%。
- 肝脾差值-10 HU的敏感度/特异度为92.1%/52.5%。
临床应用与阅片要点
- 在标准门静脉期CT上可单独使用肝脏衰减值诊断中度肝脂肪变性。
- 中度脂肪变性肝脏不仅平扫衰减值较低(<40 HU),而且增强程度较低,通常导致门静脉期肝脏衰减值≤80 HU。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the diagnostic performance of post-contrast CT for predicting moderate hepatic steatosis in an older adult cohort undergoing a uniform CT protocol, utilizing hepatic and splenic attenuation values.
MATERIALS AND METHODS: A total of 1676 adults (mean age, 68.4 ± 10.2 years; 1045M/631F) underwent a CT urothelial protocol that included unenhanced, portal venous, and 10-min delayed phases through the liver and spleen. Automated hepatosplenic segmentation for attenuation values (in HU) was performed using a validated deep-learning tool. Unenhanced liver attenuation < 40.0 HU, corresponding to > 15% MRI-based proton density fat, served as the reference standard for moderate steatosis.
RESULTS: The prevalence of moderate or severe steatosis was 12.9% (216/1676). The diagnostic performance of portal venous liver HU in predicting moderate hepatic steatosis (AUROC = 0.943) was significantly better than the liver-spleen HU difference (AUROC = 0.814) (p < 0.001). Portal venous phase liver thresholds of 80 and 90 HU had a sensitivity/specificity for moderate steatosis of 85.6%/89.6%, and 94.9%/74.7%, respectively, whereas a liver-spleen difference of -40 HU and -10 HU had a sensitivity/specificity of 43.5%/90.0% and 92.1%/52.5%, respectively. Furthermore, livers with moderate-severe steatosis demonstrated significantly less post-contrast enhancement (mean, 35.7 HU vs 47.3 HU; p < 0.001).
CONCLUSION: Moderate steatosis can be reliably diagnosed on standard portal venous phase CT using liver attenuation values alone. Consideration of splenic attenuation appears to add little value. Moderate steatosis not only has intrinsically lower pre-contrast liver attenuation values (< 40 HU), but also enhances less, typically resulting in post-contrast liver attenuation values of 80 HU or less.
CLINICAL RELEVANCE STATEMENT: Moderate steatosis can be reliably diagnosed on post-contrast CT using liver attenuation values alone. Livers with at least moderate steatosis enhance less than those with mild or no steatosis, which combines with the lower intrinsic attenuation to improve detection.
KEY POINTS: The liver-spleen attenuation difference is frequently utilized in routine practice but appears to have performance limitations. The liver-spleen attenuation difference is less effective than liver attenuation for moderate steatosis. Moderate and severe steatosis can be identified on standard portal venous phase CT using liver attenuation alone.
引用
- Pickhardt PJ, Blake GM, Moeller A, et al. Post-contrast CT liver attenuation alone is superior to the liver-spleen difference for identifying moderate hepatic steatosis. Eur Radiol. 2024. PMID: 38834787. doi:10.1007/s00330-024-10816-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。